MEASURE: Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Primary Objective
The study is a non-interventional, observational study for the purpose of prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with AML undergoing alloHCT.
Details
Age
Adult
Type of Study
Other
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Marc Schwartz, MD
Study ID
Protocol Number: 23-0054
More information available at ClinicalTrials.gov: NCT05224661
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers